At the time of writing, Kymera Therapeutics Inc [KYMR] stock is trading at $47.78, up 4.21%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The KYMR shares have gain 9.09% over the last week, with a monthly amount glided 8.49%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Kymera Therapeutics Inc [NASDAQ: KYMR] stock has seen the most recent analyst activity on April 22, 2024, when Oppenheimer initiated its Outperform rating and assigned the stock a price target of $53. On January 04, 2024, upgrade upgraded it’s rating to Overweight. BofA Securities downgraded its rating to a Neutral and decreased its price target to $30 on January 03, 2024. Wells Fargo downgraded its rating to a Equal Weight but $26 remained the price target by the analyst firm on December 19, 2023. Truist started tracking with a Buy rating for this stock on June 30, 2023, and assigned it a price target of $50. In a note dated May 05, 2023, Raymond James upgraded an Outperform rating on this stock.
For the past year, the stock price of Kymera Therapeutics Inc fluctuated between $9.60 and $49.06. Currently, Wall Street analysts expect the stock to reach $49.56 within the next 12 months. Kymera Therapeutics Inc [NASDAQ: KYMR] shares were valued at $47.78 at the most recent close of the market. An investor can expect a potential return of 3.73% based on the average KYMR price forecast.
Analyzing the KYMR fundamentals
According to Kymera Therapeutics Inc [NASDAQ:KYMR], the company’s sales were 88.55M for trailing twelve months, which represents an 55.33% jump. Gross Profit Margin for this corporation currently stands at 0.94% with Operating Profit Margin at -2.04%, Pretax Profit Margin comes in at -1.78%, and Net Profit Margin reading is -1.78%. To continue investigating profitability, this company’s Return on Assets is posted at -0.19, Equity is -0.29 and Total Capital is -0.24. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.13.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 46.44 points at the first support level, and at 45.09 for the second support level. However, for the 1st resistance point, the stock is sitting at 48.50, and for the 2nd resistance point, it is at 49.21.
Ratios To Look Out For
It is important to note that Kymera Therapeutics Inc [NASDAQ:KYMR] has a current ratio of 8.45. Also, the Quick Ratio is 8.45, while the Cash Ratio stands at 1.09. Considering the valuation of this stock, the price to sales ratio is 34.40, the price to book ratio is 4.30.
Transactions by insiders
Recent insider trading involved BAKER BROS. ADVISORS LP, Director, that happened on Aug 20 ’24 when 1.0 shares were purchased. Chief Medical Officer, Gollob Jared completed a deal on Jul 16 ’24 to sell 23145.0 shares. Meanwhile, Chief Medical Officer Gollob Jared sold 16455.0 shares on Jul 15 ’24.
